 |
|
A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic DepressionThe Study of Pharmacotherapy of Psychotic Depression (STOP-PD)
Barnett S. Meyers, MD;
Alastair J. Flint, MD;
Anthony J. Rothschild, MD;
Benoit H. Mulsant, MD;
Ellen M. Whyte, MD;
Catherine Peasley-Miklus, PhD;
Eros Papademetriou, MA;
Andrew C. Leon, PhD;
Moonseong Heo, PhD; for the STOP-PD Group
Arch Gen Psychiatry. 2009;66(8):838-847.
Context Evidence for the efficacy of combination pharmacotherapy has been limited and without positive trials in geriatric patients with major depression (MD) with psychotic features.
Objectives To compare remission rates of MD with psychotic features in those treated with a combination of atypical antipsychotic medication plus a serotonin reuptake inhibitor with those treated with antipsychotic monotherapy; and to compare response by age.
Design Twelve-week, double-blind, randomized, controlled trial.
Setting Clinical services of 4 academic sites.
Patients Two hundred fifty-nine subjects with MD with psychotic features randomized by age (<60 or  60 years) (mean [standard deviation (SD)], 41.3 [10.8] years in 117 younger adults vs 71.7 [7.8] years in 142 geriatric participants).
Intervention Target doses of 15 to 20 mg of olanzapine per day plus masked sertraline or placebo at 150 to 200 mg per day.
Main Outcome Measure Remission rates of MD with psychotic features.
Results Treatment with olanzapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.12-1.47; P < .001); 41.9% of subjects who underwent combination therapy were in remission at their last assessment compared with 23.9% of subjects treated with monotherapy ( 21 = 9.53, P = .002). Combination therapy was comparably superior in both younger (OR, 1.25; 95% CI, 1.05-1.50; P = .02) and older (OR, 1.34; 95% CI, 1.09-1.66; P = .01) adults. Overall, tolerability was comparable across age groups. Both age groups had significant increases in cholesterol and triglyceride concentrations, but statistically significant increases in glucose occurred only in younger adults. Younger adults gained significantly more weight than older subjects (mean [SD], 6.5 [6.6] kg vs 3.3 [4.9] kg, P = .001).
Conclusions Combination pharmacotherapy is efficacious for the treatment of MD with psychotic features. Future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks.
Trial Registration clinicaltrials.gov Identifier: NCT00056472
Author Affiliations: Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, White Plains, New York (Drs Meyers, Peasley-Miklus, Leon, and Heo, and Mr Papademetriou); Department of Psychiatry, University of Toronto and University Health Network, Toronto, Ontario, Canada (Drs Flint and Mulsant); Geriatric Program and Research Institute, Toronto Rehabilitation Institute, and Toronto General Research Institute, Toronto (Dr Flint); University of Massachusetts Medical School and University of Massachusetts Memorial Health Care, Worcester (Dr Rothschild); Centre for Addiction and Mental Health, Toronto (Dr Mulsant); and Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Drs Mulsant and Whyte). Dr Heo is now at Albert Einstein College of Medicine, Bronx, New York.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(8):808.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Antipsychotic Drugs Still Necessary for Psychotic Depression
JWatch Psychiatry 2009;2009:2-2.
FULL TEXT
|
